Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice
| Autor: | Lorena Pérez Albaladejo, Alfonso González Utrilla, Irene Notario Ferreira, Pilar Morales Garrido, María José Soto Pino, Evelyn Suero Rosario, Cristina Caro Hernández, Antonio García Sanchez, Miguel Angel Ferrer González, Rafael Cáliz, Isabel Añón Oñate |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
musculoskeletal diseases
Adult Male medicine.medical_specialty Combination therapy Kaplan-Meier Estimate Antibodies Monoclonal Humanized Drug Administration Schedule Arthritis Rheumatoid 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Tocilizumab Internal medicine medicine Rheumatoid factor Humans 030212 general & internal medicine Longitudinal Studies Prospective Studies skin and connective tissue diseases Adverse effect Aged 030203 arthritis & rheumatology business.industry General Medicine Retention rate Middle Aged medicine.disease Surgery Discontinuation Treatment Outcome chemistry Rheumatoid arthritis Antirheumatic Agents Drug Therapy Combination Female business Rheumatism |
| Zdroj: | Reumatologia clinica. 13(2) |
| ISSN: | 1885-1398 |
| Popis: | Objectives To evaluate the efficacy of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) in clinical practice, retention rates of the drug and predictors of response. Methods We performed a descriptive, prospective, longitudinal, open-label study in patients receiving TCZ (8 mg/kg/4 weeks) in a clinical practice setting. The clinical responses were evaluated using the European League Against Rheumatism (EULAR) response criteria, and the low activity and remission rates according to the Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) and the Clinical Disease Activity Index (CDAI). Results The EULAR response rate was 86.63% and the DAS28 remission rate was 53.7% after 6 months of treatment; rates of low disease activity were 52.9% on CDAI and 47.1% on DAS28 at month 24. There were no statistically significant differences in EULAR response, rates of low activity and remission on DAS28 between patients receiving TCZ alone and those receiving TCZ in combination therapy, or between patients positive or negative for rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies. The naive biological therapy patients showed better remission and low activity rates after 6 months of treatment. The retention rate was 61% at month 24. Adverse events were among the most frequent causes of discontinuation. Conclusions Tocilizumab is effective in RA, has a similar efficacy when used alone or in combination with synthetic disease-modifying antirheumatic drugs (DMARDs) and shows high retention rates. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|